Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission

Cingulate boosted cash reserves but losses and expenses continue to climb ahead of FDA resubmission.

What the company is saying

Cingulate Inc. is emphasizing that it has nearly finished the manufacturing work required to address the FDA’s chemistry, manufacturing, and controls (CMC) requests for its lead ADHD drug candidate, CTx-1301. The company states it expects to resubmit the new drug application (NDA) between December 2026 and January 2027, highlighting that the FDA’s prior Complete Response Letter did not question the drug’s clinical safety or efficacy. Management, led by Chairman and CEO Shane J. Schaffer, frames the update as a near-term regulatory milestone and thanks shareholders for their patience. The narrative stresses a strengthened cash position—$23.2 million as of September 30, 2026, up from $11.0 million at year-end 2025—attributed to a $12.0 million private placement and $22.5 million raised through agreements with AGP and Lincoln Park Capital, offset by $20.4 million in operational outflows. The company acknowledges sharply higher SG&A expenses, driven by commercial readiness activities and expanded work with commercialization partner Indegene. The tone is measured, focusing on operational progress and liquidity, while acknowledging continued losses.

What the data suggests

Cingulate ended Q3 2026 with $23,185,900 in cash and cash equivalents, nearly doubling its year-end 2025 balance due to $12,000,000 from a private placement and $22,500,000 from equity agreements, offset by $20,400,000 in operational cash burn. Working capital rose to $18,832,234 from $1,695,633. R&D expenses for the quarter were $2,910,660, up 2.2% year-over-year, mainly due to increased manufacturing costs for CTx-1301, while nine-month R&D fell 15.3% to $6,581,803 as clinical and regulatory costs declined. SG&A expenses surged 45.5% for the quarter to $4,580,358 and 116.6% for the nine months to $14,247,412, reflecting commercial build-out and Indegene partnership activities. Net loss widened to $7,731,397 for the quarter and $22,913,750 for the nine months, up from $7,341,062 and $16,177,001, respectively, primarily due to higher SG&A. The accumulated deficit reached $155,288,781. The company projects its cash will fund operations into mid-2027. The NDA resubmission for CTx-1301 is expected within two months, with FDA review timelines of two to six months post-resubmission, but approval is not assured. No revenue figures are disclosed, consistent with a pre-commercial stage. The financial trajectory shows increased losses and expense growth despite improved liquidity.

Analysis

The announcement is measured in tone and primarily factual, with detailed financial disclosures and a clear update on regulatory progress for CTx-1301. Most claims are realised and supported by numerical data, such as cash position, working capital, and net loss. Forward-looking statements are limited to the expected NDA resubmission timeline and anticipated FDA review period, both of which are concrete and near-term (within 2-8 months). The company has raised significant capital to fund operations and commercial readiness, but there is no overstatement of imminent revenue or approval. The main gap is that while manufacturing work is described as 'substantially completed,' no documentary evidence is provided for this milestone, and the regulatory outcome remains pending. The financial trajectory is deteriorating due to increased losses and expenses, but this is not obscured or spun positively. Overall, the narrative is proportionate to the evidence, with minimal promotional language.

Risk flags

• ●Cingulate’s operating losses are accelerating, with net loss for the nine months ended September 30, 2026 reaching $22,913,750, up from $16,177,001 the prior year. This trend, combined with a $155,288,781 accumulated deficit, signals ongoing high cash burn and the need for future capital if commercial revenues do not materialize rapidly.
• ●SG&A expenses more than doubled year-over-year for the nine months, rising to $14,247,412 from $6,579,735, largely due to commercial readiness and partnership activities. This rapid cost escalation ahead of product approval increases financial risk if regulatory or commercial milestones are delayed or missed.
• ●The NDA resubmission for CTx-1301 is not yet complete, and while manufacturing work is described as 'substantially completed,' no documentary evidence is provided. Regulatory approval remains uncertain, and any further FDA requests could delay or derail commercialization plans.
• ●Cingulate’s current cash position of $23,185,900 is projected to fund operations only into mid-2027. If CTx-1301 approval or commercial launch is delayed, the company may require additional dilutive financing or face liquidity constraints.

Bottom line

Cingulate has significantly improved its cash and working capital positions through $34.5 million in new financing, but this has not translated into improved operating performance, as losses and expenses continue to rise. The company is nearing a key regulatory milestone with the planned NDA resubmission for CTx-1301, but approval is not guaranteed and the timeline for commercial revenue remains uncertain. The sharp increase in SG&A spending, driven by commercial readiness and the Indegene partnership, adds pressure to deliver regulatory and commercial success within the current cash runway, which extends only into mid-2027. Investors should focus on the NDA resubmission and FDA review outcomes as the next major catalysts, while monitoring cash burn and any further capital raises. The most important takeaway is that Cingulate’s financial sustainability now hinges on timely regulatory progress and successful commercialization of CTx-1301.

Announcement summary

(NASDAQ:CING) Cingulate Inc. reported financial results for the quarter ended September 30, 2026, and provided an update on the regulatory status of its lead ADHD asset, CTx-1301. The company has substantially completed the manufacturing work required to address the FDA’s chemistry, manufacturing and controls (CMC) information requests for CTx-1301, following a Complete Response Letter (CRL) issued by the FDA on June 1, 2026. Cingulate expects to resubmit the new drug application (NDA) for CTx-1301 between December 2026 and January 2027. The FDA’s CRL did not raise concerns about the clinical safety or efficacy of CTx-1301. After resubmission, the FDA is expected to classify the NDA as a Class 1 or Class 2 resubmission, with review goals of two and six months, respectively. As of September 30, 2026, Cingulate had approximately $23,185,900 in cash and cash equivalents, compared to $10,953,383 as of December 31, 2025. The increase in cash was primarily due to capital raised during the first nine months of 2026, including a $12,000,000 private placement in the first quarter and $22,500,000 of capital raised through an At-the-Market Agreement with AGP and a Purchase Agreement with Lincoln Park Capital, partially offset by $20,400,000 in cash used for operations. Working capital as of September 30, 2026 was $18,832,234, up from $1,695,633 at December 31, 2025. Research and development expenses were $2,910,660 for the three months ended September 30, 2026, up from $2,848,544 for the same period in 2025, and $6,581,803 for the nine months ended September 30, 2026, down from $7,772,109 for the same period in 2025. Selling, general and administrative expenses were $4,580,358 for the three months ended September 30, 2026, compared to $3,147,291 for the same period in 2025, and $14,247,412 for the nine months ended September 30, 2026, compared to $6,579,735 for the same period in 2025. Net loss was $7,731,397 for the three months ended September 30, 2026, compared to $7,341,062 for the same period in 2025, and $22,913,750 for the nine months ended September 30, 2026, compared to $16,177,001 for the same period in 2025. Total assets as of September 30, 2026 were $28,150,677, with total liabilities of $7,383,547 and total stockholders' equity of $20,767,130. The company’s accumulated deficit as of September 30, 2026 was $155,288,781. Cingulate’s commercialization partner is Indegene. The company believes its cash and cash equivalents will be sufficient to fund operations into mid-2027, including costs associated with seeking regulatory approval for CTx-1301 and continuing the build-out of commercial readiness capabilities. CTx-1301 is a once-daily, multi-core tablet utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™) platform, and is being evaluated for the treatment of ADHD under the FDA’s 505(b)(2) pathway. The PTR platform incorporates a proprietary Erosion Barrier Layer (EBL) formulation, Oralogik™, licensed from BDD Pharma.

Disagree with this article?